Influenza Virus Vaccine
Moderate
Textbook
Small increase in febrile seizures.
The increase of febrile seizures when combining these vaccines is small, and the CDC does not recommend delivering them on separate days.
Source: G&G 14e · p812
Drug reference
pneumococcal conjugate vaccine
conjugated bacterial polysaccharide vaccine · vaccine
conjugated bacterial polysaccharide vaccinevaccine
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
This vaccine utilizes technology to bind polysaccharide from the bacterial capsule to a carrier protein (often diphtheria or tetanus toxoid), which induces type-specific antipolysaccharide antibodies and provides long-term protection, particularly in infants.
Indications
prevention of invasive diseases caused by Streptococcus pneumoniae in infants and young children, including meningitis, bacteremia and sepsis, and pneumonia
Dosing
- Pediatric
- Infants are given a primary series of PCV13 at ages 2, 4, and 6 months, with a booster at 12 to 15 months.
Drug interactions
Related guidelines
Extrapulmonary tuberculosis
ICMR · Infectious Diseases · 2022
Community-acquired pneumonia
IDSA · Pulmonology · 2019
Community-acquired pneumonia
ICMR · Pulmonology · 2022
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Childhood pneumonia and respiratory infection
MOHFW · Paediatrics · 2021
Other conjugated bacterial polysaccharide vaccine drugs
Ask House about pneumococcal conjugate vaccine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team